News ACC25: Positive results with Lilly's Lp(a)-lowering drug Eli Lilly's lepodisiran has been shown to reduce Lp(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial.
News AHA: One dose of Lilly’s siRNA drug cuts Lp(a) for a year A first-in-human trial of Eli Lilly’s experimental RNA interference drug lepodisiran has shown that just one dose reduced lipoprotein(a) – a risk factor for cardiovascular
News RFK Jr spreading 'harmful myths' on Alzheimer's research The Alzheimer's Association has hit out at "inaccurate and dangerous fabrications" by HHS Secretary Robert F Kennedy Jr about NIH dementia research.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.